May 29 (Reuters) - Prescient Therapeutics Ltd (PTX)
- updates on its clinical trials with PTX-200 following a serious adverse event in a late-stage patient on its breast cancer trial.
- subsequent to preliminary safety and efficacy analyses, last patient enrolled in trial experienced a sae and passed away
- ptx has temporarily paused recruitment to each of its PTX-200 trials
- intends to re-commence enrollment following formal lifting of clinical holds by FDA
